Overexpression of both miRNAs inhibits cardiac hypertrophy, and inhibition of miR-133 causes significant cardiac hypertrophy and cardiac dysfunction via upregulation of the miR-133 targets Rho1, Cdc42, and Nelf-A/WHSC2 in vivo, suggesting miR-133 is cardioprotective in the context of hypertrophy (Carè et al., 2007). Here, NELFA is linked to cardiac hypertrophy.